Skip to main content
American Journal of Respiratory and Critical Care Medicine logoLink to American Journal of Respiratory and Critical Care Medicine
editorial
. 2012 Sep 1;186(5):395–396. doi: 10.1164/rccm.201206-1092ED

Obesity: Changing Asthma in the 21st Century

Anne E Dixon 1
PMCID: PMC3443799  PMID: 22942341

The world is witnessing a major shift in human disease swept in by an unprecedented pandemic, obesity (1). This is changing the nature and presentation of health and disease. An obvious example is type II diabetes; once a disease of elderly overweight adults, this condition is now increasingly diagnosed in children. Lung health is no exception to this new era in human health. Obesity is a major risk factor for asthma. This has been reported in adults and children, in multiple demographic groups, and from countries around the world (2). Asthma in obesity tends to be characterized by poor control (3) and decreased responsiveness to standard controller therapies (4). The epidemiological evidence linking asthma and obesity is compelling.

While the epidemiological evidence linking asthma and obesity is impressive, the mechanistic link between these diseases is far from clear. Obesity has important effects on airway physiology (5), though the relationship between obesity and asthma is far more complex than might be anticipated from simple mass loading. Important insights into the relationship may be gained from recent work on mouse models of obesity and asthma, and also from understanding the changes in adipose tissue and metabolism that take place with obesity. Insights from these basic studies need to be translated into the context of the human airway, and the publication by Lugogo and colleagues in this issue of the Journal (pp. 404–411) represents an important step in this direction (6).

Work in mouse models of obesity and asthma has provided important clues into the potential nature of the relationship in humans (7). Airway reactivity is increased in obese mice, even without airway challenge (7). Adipokines such as leptin and adiponectin and cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) appear to be involved in the pathogenesis of airway disease in obese mice (8). Studies in mice have provided a window into potential pathways that may link obesity and asthma in humans.

The last decade has seen major advances in our understanding of the pathophysiology of obesity. Adipose tissue is far from a passive energy storage depot; it is an important endocrine organ with major effects on immune function (9). In lean individuals, alternatively activated macrophages and eosinophils are found in adipose tissue. With obesity, macrophages in adipose tissue expand and take on a proinflammatory M1 phenotype elaborating cytokines such as IL-6, IL-1β, and TNF-α (10). Changes in macrophage function have been reported in organs other than adipose tissue: Kupfer cell function is altered in the liver, contributing to the development of steatohepatitis (10). These changes in immune function could have profound effects on the pathogenesis of airway disease if they also occur in the human lung.

Studies suggest that alveolar macrophage function may be altered in obesity. Mancuso and colleagues have shown that alveolar macrophage function is altered in leptin-deficient mice: macrophages from obese mice have impaired phagocytosis and abnormalities in leukotriene production (11, 12). This has important implications for host defense. Sutherland and colleagues, in the only previous study of alveolar macrophages isolated from overweight and obese human individuals with asthma, found impaired responsiveness to dexamethasone, of obvious relevance for the steroid resistance typical of obese asthma (13). In the article published in this issue of the Journal by Lugogo and colleagues, obese individuals with asthma were found to have altered response both to lipopolysaccharide and to lipopolysaccharide combined with leptin, when compared with obese control subjects, lean subjects with asthma, and lean control subjects. The investigators were careful to try and exclude the use of steroids, which could affect macrophage function, and although the levels of leptin used in the in vitro experiments were higher than that typically reported in obese individuals with asthma (250 ng/ml compared with 20–30 ng/ml in serum [14]), this study is important because it suggests that altered alveolar macrophage function and altered innate immunity are likely to be important features of asthma in obesity.

In addition to changes in macrophage function, the investigators made some noteworthy observations regarding bronchoalveolar lavage cytokines: TNF-α and leptin were particularly elevated in obese individuals with asthma. TNF-α has also been implicated in mouse studies of obesity and asthma (15). Given the therapeutic relevance of this pathway, this observation likely warrants further investigation. Leptin was also particularly elevated in bronchoalveolar lavage fluid of obese individuals with asthma. Shore and coworkers have previously shown that leptin infusion increases airway reactivity in lean mice; this is not related to increases in allergic airway inflammation, suggesting that leptin may be having effects in pathways quite distinct from those involved in allergic asthma (16). The observation that leptin was inversely related to lung function as measured by FEV1 is also intriguing, given reports that leptin is involved in lung development (17, 18) and may regulate fibroproliferative responses in the lung (19). Further studies evaluating the mechanistic relevance of elevated TNFα and leptin in airway disease in obese individuals with asthma are needed.

The study by Lugogo and colleagues has important implications for our understanding of obesity and asthma. Obesity perturbs immune function, and many of the circulating factors produced by adipose tissue may have effects on airway disease in obese individuals with asthma. It is likely that this leads to a quite different form of asthma than that typically associated with allergic airway disease. This likely explains the lack of response to standard therapies. Therapies developed based on insights gained from the study of lean allergic mouse models of asthma likely have limited relevance for asthma in obesity. Studies such as that of Lugogo and coworkers are essential if we are to understand airway disease in the 21st century.

Supplementary Material

Disclosures

Footnotes

Supported by NIH grant P30 GM 103532.

Author disclosures are available with the text of this article at www.atsjournals.org.

References

  • 1.Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, Singh GM, Gutierrez HR, Lu Y, Bahalim AN, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet 2011;377:557–567 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Beuther DA, Sutherland ER. Overweight, obesity, and incident asthma: a meta-analysis of prospective epidemiologic studies. Am J Respir Crit Care Med 2007;175:661–666 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Vortmann M, Eisner MD. BMI and health status among adults with asthma. Obesity (Silver Spring) 2008;16:146–152 [DOI] [PubMed] [Google Scholar]
  • 4.Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Eur Respir J 2006;27:495–503 [DOI] [PubMed] [Google Scholar]
  • 5.Salome CM, King GG, Berend N. Physiology of obesity and effects on lung function. J Appl Physiol 2010;108:206–211 [DOI] [PubMed] [Google Scholar]
  • 6.Lugogo NL, Hollingsworth JW, Howell DL, Que LG, Francisco D, Church TD, Potts-Kant EN, Ingram JL, Wang Y, Jung S-H, et al. Alveolar macrophages from overweight/obese subjects with asthma demonstrate a proinflammatory phenotype. Am J Respir Crit Care Med 2012;186:404–411 [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  • 7.Shore SA. Obesity and asthma: lessons from animal models. J Appl Physiol 2007;102:516–528 [DOI] [PubMed] [Google Scholar]
  • 8.Shore SA. Obesity, airway hyperresponsiveness, and inflammation. J Appl Physiol 2010;108:735–743 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Mathis D, Shoelson SE. Immunometabolism: an emerging frontier. Nat Rev Immunol 2011;11:81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Osborn O, Olefsky JM. The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 2012;18:363–374 [DOI] [PubMed] [Google Scholar]
  • 11.Mancuso P, Gottschalk A, Phare SM, Peters-Golden M, Lukacs NW, Huffnagle GB. Leptin-deficient mice exhibit impaired host defense in gram-negative pneumonia. J Immunol 2002;168:4018–4024 [DOI] [PubMed] [Google Scholar]
  • 12.Mancuso P, Peters-Golden M, Goel D, Goldberg J, Brock TG, Greenwald-Yarnell M, Myers MG., Jr Disruption of leptin receptor-STAT3 signaling enhances leukotriene production and pulmonary host defense against pneumococcal pneumonia. J Immunol 2011;186:1081–1090 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med 2008;178:682–687 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Sutherland ER, Goleva E, King TS, Lehman E, Stevens AD, Jackson LP, Stream AR, Fahy JV. Cluster analysis of obesity and asthma phenotypes. PLoS ONE 2012;7:e36631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Williams AS, Chen L, Kasahara DI, Wurmbrand AP, Shore SA. Obesity and airway responsiveness: role of TNFR2. Pulm Pharmacol Ther 2012; Epub ahead of print [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shore SA, Schwartzman IN, Mellema MS, Flynt L, Imrich A, Johnston RA. Effect of leptin on allergic airway responses in mice. J Allergy Clin Immunol 2005;115:103–109 [DOI] [PubMed] [Google Scholar]
  • 17.Huang K, Rabold R, Abston E, Schofield B, Misra V, Galdzicka E, Lee H, Biswal S, Mitzner W, Tankersley CG. Effects of leptin deficiency on postnatal lung development in mice. J Appl Physiol 2008;105:249–259 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kirwin SM, Bhandari V, Dimatteo D, Barone C, Johnson L, Paul S, Spitzer AR, Chander A, Hassink SG, Funanage VL. Leptin enhances lung maturity in the fetal rat. Pediatr Res 2006;60:200–204 [DOI] [PubMed] [Google Scholar]
  • 19.Jain M, Budinger GR, Lo A, Urich D, Rivera SE, Ghosh AK, Gonzalez A, Chiarella SE, Marks K, Donnelly HK, et al. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-gamma. Am J Respir Crit Care Med 2011;183:1490–1498 [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Disclosures

Articles from American Journal of Respiratory and Critical Care Medicine are provided here courtesy of American Thoracic Society

RESOURCES